Phòng Khám BS Quang

Giới thiệu Khoa

- Tên khoa: Khoa Nội Tim mạch

- Vị trí: BVĐKTW Quảng Nam, Tầng 5, Khu nhà A

- Trưởng khoa: Ts.Bs. Phan Tấn Quang. ĐT: 0934.998.667

- Phó khoa: Bs CKI. Nguyễn Thanh Bình (0975.376.978), Ths. Bs. Trác Hoài Hải (0971.197.204)

- Số giường: 90

- Nhân lực: 34 người, trong đó: Tiến sĩ 01, Bs Nội trú: 02, Thạc sĩ: 01, BSCKI: 03, DD CKI 01.

- Chuyên môn: Điều trị các bệnh lý tim mạch và nội tiết

- Kỹ thuật: Các kỹ thuật can thiệp tim mạch và nội khoa

Hình ảnh liên quan hoạt động khoa

Điểm CHA₂DS₂-VASc	Phân độ nguy cơ	Ý nghĩa lâm sàng
0	1	Thấp	Nguy cơ rất thấp
1	2	Trung gian	Có nguy cơ thực
≥ 2	≥ 3	Cao	Nguy cơ đột quỵ rõ

Điểm CHA₂DS₂-VASc	Nguy cơ đột quỵ thiếu máu não (%)	Nguy cơ đột quỵ / TIA / thuyên tắc hệ thống (%)
0	0,2	0,3
1	0,6	0,9
2	2,2	2,9
3	3,2	4,6
4	4,8	6,7
5	7,2	10,0
6	9,7	13,6
7	11,2	15,7
8	10,8	15,2
9	12,2	17,4

TÀI LIỆU THAM KHẢO

Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach. Chest. 2010;137(2):263–272. PubMed
Lip GY, Halperin JL. Improving stroke risk stratification in atrial fibrillation. Am J Med. 2010;123(6):484–488. PubMed
Cairns JA. CHA₂DS₂-VASc had better discrimination than CHADS₂ for predicting risk for thromboembolism in atrial fibrillation. Ann Intern Med. 2011;154(10):JC5–13. PubMed
Olesen JB, Lip GY, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation. BMJ. 2011;342:d124. PubMed
Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in atrial fibrillation. Eur Heart J. 2012;33(12):1500–1510. PubMed
Okumura K, Inoue H, Atarashi H, et al. Validation of CHA₂DS₂-VASc and HAS-BLED scores in Japanese patients. Circ J. 2014;78(7):1593–1599. PubMed
Chao TF, Liu CJ, Wang KL, et al. Using the CHA₂DS₂-VASc score for refining stroke risk stratification in low-risk Asian patients. J Am Coll Cardiol. 2014;64(16):1658–1665. PubMed
January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. J Am Coll Cardiol. 2014. PubMed
Gage BF, Andrade A. Various risk stratification schemes predict ischemic stroke and bleeding in atrial fibrillation. Ann Intern Med. 2012;157(8):JC4–13. PubMed
van Doorn S, Debray TPA, Kaasenbrood F, et al. Predictive performance of the CHA₂DS₂-VASc rule in atrial fibrillation. J Thromb Haemost. 2017;15(6):1065–1077. PubMed
Lip GY, Nielsen PB. Should patients with atrial fibrillation and 1 stroke risk factor be anticoagulated? Circulation. 2016;133:1498–1503. PubMed
Fauchier L, Clementy N, Ivanes F, et al. Should atrial fibrillation patients with only 1 nongender-related CHA₂DS₂-VASc risk factor be anticoagulated? Stroke. 2016;47:1831–1836. PubMed
Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation. Circulation. 2024;149:e1–e156. PubMed
Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation. Eur Heart J. 2024. PubMed
Teppo K, Lip GYH, Airaksinen KEJ, et al. Comparing CHA₂DS₂-VA and CHA₂DS₂-VASc scores. Lancet Reg Health Eur. 2024;43:100967. PubMed
Bungo B, Chaudhury P, Arustamyan M, et al. CCHA₂DS₂-VASc score incorporating cancer. Int J Cardiol Heart Vasc. 2022;41:101072. PubMed
Champsi A, Mobley AR, Subramanian A, et al. Gender and contemporary risk of adverse events in atrial fibrillation. Eur Heart J. 2024. PubMed